Up next

CEOs, Senior Executives Highlight Strategies, M&A, and Expansions at DCAT Week

Chief executive officers and senior executives from DCAT member companies provided key updates on strategy, mergers and acquisitions, and expansions at the DCAT Member Company Announcement Forum held during DCAT Week in mid-March.

The executives highlighted key company activity impacting the pharmaceutical manufacturing value chain. SCHOTT, Catalent, Thermo Fisher Scientific, Cambrex, Lonza, BSP Pharmaceuticals, Servier CDMO, Selkirk Pharma, Seqens, Cerbios-Pharma, and ACG were among the companies taking the podium to provide their latest developments (see announcements below).

SCHOTT Plans $1-Billion Expansion in Pharma Packaging

Catalent Investing $214 Million to Expand Biologics Capabilities; Invests in Oral Delivery Capabilities

Thermo Fisher Scientific Investing $150 Million in Sterile Injectables Development and Manufacturing

Cambrex Updates Integration of Halo Pharma and Avista Pharma; Expands Small-Molecule API Mfg

Lonza Updates $100-Million Expansion for High-Potency APIs and Small-Molecule Mfg

BSP To Add High-Containment Capacity for Conjugation and Injectable Drug Products

Servier CDMO Invests $55 Million for Bioproduction and $7 Million for Industrial Prep Chromatography

New CDMO Selkirk Pharma Investing $30 Million in Aseptic Fill–Finish Facility

Seqens Investing $30 Million to Expand High-Potency Manufacturing

Cerbios-Pharma Investing in New High-Potency API Production Line and Conjugation Suite

ACG Expands Capsule Production in Brazil, India, and Croatia

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

FDA Begins Pilot To Incentivize US-Based Pharma Manufacturing

By
FDA has selected seven companies to participate in the agency’s PreCheck Pilot Program, a new initiative designed to incentivize US-based pharma manufacturing and facilitate operational readiness of greenfield facilities. Which companies were selected, and what does the program entail?

Mid-Year Review: What’s Trending in New Drug Approvals?

By
FDA’s Center for Drug Evaluation and Research has approved 24 new drugs thus far in 2026. Which companies and drug candidates have crossed the finish line, and how is the product mix between small molecules and biologics faring?

New CEO Takes the Helm of Takeda: What’s Next?

By
In a planned succession, Julie Kim took the helm at Takeda as President and CEO with former President and CEO Christophe Weber stepping down following a 12-year tenure. The company faces a transitional period as it seeks to return to growth. What’s the plan?
Wave

The State of the State: Continuous Manufacturing

By
FDA’s Emerging Technology Program, a collaborative program between the agency and industry, aims to facilitate bio/pharma companies’ adoption of new manufacturing technologies, including continuous manufacturing. Where do things stand?